•HRES 1203 IH 
Whereas the 5-year survival rate for glioblastoma patients is 
only 6.9 percent, and the median length of survival for 
glioblastoma patients is only 8 months; 
Whereas glioblastoma is described as a disease that affects 
the ‘‘essence of self’’, as the treatment and removal of 
glioblastoma presents significant challenges due to the 
uniquely complex and fragile nature of the brain, the pri-
mary organ in the human body that controls not only 
cognitive ability, but also the actions of every organ and 
limb; 
Whereas patients and caregivers play a critical role in fur-
thering research for glioblastoma; 
Whereas, relative to other types of cancers, brain cancer pa-
tients pay the second highest out-of-pocket costs for med-
ical services in both the initial and end-of-life phases of 
care; 
Whereas, although research advances may fuel the develop-
ment of new treatments for glioblastoma, challenging ob-
stacles to accelerating progress toward new treatments 
for glioblastoma remain, and there are no screening or 
early detection methods; 
Whereas, in 2021, the World Health Organization reclassified 
brain tumors and made significant changes to the molec-
ular characteristics of a glioblastoma diagnosis, necessi-
tating critical biomarker testing for patients suspected of 
having a possible glioblastoma; 
Whereas, although glioblastoma was first described in medical 
and scientific literature in the 1920s, and despite its dev-
astating prognosis, only 5 drugs and 1 medical device 
have been approved by the Food and Drug Administra-
tion to specifically treat glioblastoma since the 1920s, 
VerDate Sep 11 2014 
03:59 May 07, 2024
Jkt 049200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\HR1203.IH
HR1203
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 1203 IH 
and the mortality rates associated with glioblastoma have 
changed little during the past 30 years; 
Whereas, since the first Glioblastoma Awareness Day, the 
National Cancer Institute established the Glioblastoma 
Therapeutics Network (referred to in this preamble as 
‘‘GTN’’) in 2020 as part of a national infrastructure to 
enhance and support the discovery and development of 
glioblastoma therapies available for multi-institutional 
GTN teams to drive therapeutic agents through pre-
clinical studies and early phase clinical trials, which are 
necessary to rapidly evaluate potential treatments to ad-
vance toward cures and improved quality of life; 
Whereas there is a need for greater public awareness of glio-
blastoma, including awareness of both— 
(1) the urgent unmet medical needs of glioblastoma 
patients; and 
(2) the opportunities for research of, and treatment 
advances for, glioblastoma; and 
Whereas the House of Representatives supports designating 
July 17, 2024, as ‘‘Glioblastoma Awareness Day’’: Now, 
therefore, be it 
Resolved, That the House of Representatives— 
(1) expresses support for the designation of 
‘‘Glioblastoma Awareness Day’’; 
(2) encourages increased public awareness of 
glioblastoma; 
(3) honors the individuals who have died from 
the devastating disease of glioblastoma or are cur-
rently living with the disease; 
VerDate Sep 11 2014 
03:59 May 07, 2024
Jkt 049200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\HR1203.IH
HR1203
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 1203 IH 
(4) supports efforts to develop better treat-
ments for glioblastoma that will improve the long- 
term prognosis for, and the quality of life of, individ-
uals diagnosed with the disease; 
(5) recognizes the importance of molecular bio-
marker testing to the diagnosis and treatment of 
glioblastoma; 
(6) expresses support for the individuals who 
are battling brain tumors, as well as the families, 
friends, and caregivers of those individuals; 
(7) urges a collaborative approach to brain 
tumor research among governmental, private, and 
nonprofit organizations, which is a promising means 
of advancing the understanding and treatment of 
glioblastoma; and 
(8) encourages continued investments in glio-
blastoma research and treatments, including through 
the Glioblastoma Therapeutics Network and other 
existing brain tumor research resources. 
Æ 
VerDate Sep 11 2014 
03:59 May 07, 2024
Jkt 049200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\HR1203.IH
HR1203
kjohnson on DSK7ZCZBW3PROD with $$_JOB